I look forward to driving the ambitious growth strategy of REGISTRAT-MAPI in the expanding global market of Late Phase studies
Lexington, KY, USA (PRWEB) November 12, 2010
REGISTRAT-MAPI, a global Late Phase CRO, is delighted to announce the appointment of Nigel Page to the position of Chief Executive Officer for REGISTRAT-MAPI Europe.
Mr. Page has a successful track record with more than 27 years of experience in the pharmaceutical and CRO industries and has demonstrated unique capabilities in building profitable organizations in complex, multidisciplinary, global environments. He has worked for a variety of pharmaceutical and CRO companies within the UK, US, and Germany, and has held key roles in Sales & Marketing, Regulatory, Clinical Operations, Systems & Quality Improvement, IT, M&A and General/Executive Management. Mr. Page joins REGISTRAT-MAPI from i3, where he held positions of President, i3 Research and Executive Vice President, Strategic Outsourcing & Corporate Development for the last 7 years.
"Nigel is a world-recognized leader in the CRO industry and very clear about the business imperatives of a fast-moving company. He has enjoyed success in realizing aggressive growth and profitability objectives; establishing global operations and building strategic customer relationships across the world. The expertise which Nigel will bring to our Group including his leadership and management skills, industry knowledge and customer-centric philosophy will benefit not just REGISTRAT-MAPI but our client-base too,” said MAPI Group President Bernard Jambon.
Commenting on his new appointment, Mr. Page adds, "I look forward to driving the ambitious growth strategy of REGISTRAT-MAPI in the expanding global market of Late Phase studies.”
To further enhance REGISTRAT-MAPI’s drive for industry leadership in Late Phase research, Nicolaas Laarman has been appointed as Global Chief Information Officer (CIO).
In this role, Mr. Laarman will coordinate both the EU and US IT teams of REGISTRAT-MAPI in conjunction with the multidisciplinary IT needs of the entire collection of MAPI Group companies (CRO, Linguistic Validation and Strategic Consulting). His appointment will give REGISTRAT-MAPI the opportunity to maintain the proven track record of industry-leading IT services and lead the group to the next level of technological excellence.
Mr. Laarman brings an impressive background of experience to this position, notably from a career which started at Ipsen Beaufour and most recently as Global CIO of Atari. At Atari, he efficiently managed an IT Team spanning 12 countries, and developed multiple internal proprietary software solutions. He successfully audited and integrated all US acquisitions, coordinated the implementation of ERP systems and federated multi-cultural working environments. Mr. Laarman is a Dutch citizen, perfectly fluent in Dutch, French and English.
“Nicolaas clearly brings vast IT experience to REGISTRAT-MAPI, particularly at this phase of our international strategy. He is a key member of our international leadership as we continue to further globalize and synergize all of the MAPI Group companies,” stated Bernard Jambon.
REGISTRAT-MAPI, the industry's largest leading global clinical research organization (CRO) dedicated solely to 'real life' late phase clinical research, has extensive experience in the design, implementation and management of pre- and post-approval studies for biopharmaceutical and medical device clients. Our recent experience includes successful studies that reach into more than 32 countries. REGISTRAT-MAPI provides integrated clinical development services worldwide with offices in: Philadelphia, PA; Lexington, KY; Paris and Lyon, France; Rome, Italy; London, England; Utrecht, Netherlands; and Frankfurt, Germany. For more information about REGISTRAT-MAPI visit http://www.registratmapi.com or call +1 859-967-9271.
About MAPI Group
Founded in 1974, MAPI Group is a multi-disciplinary provider of research services to the biopharmaceutical industry based in Lyon, France with offices throughout Europe, US, and Japan. Other holdings of the MAPI Group include MAPI Values, the MAPI Institute, JNBD, and ProSanos. The MAPI Group companies provide clients with innovative global solutions in:- Strategic Consulting (including Patient Reported Outcomes in clinical research,Clinical & Economic Evidence and Market Access)- Late Phase CRO (Observational & Registries studies, Phase IV studies, RiskManagement Plan and Direct Patient Management)- Linguistic and Cultural validation of Patient and Clinician Assessments. For more information about MAPI Group visit http://www.mapigroup.com or call +33 (0)4 72 13 66 93.
Amy Wynn, Manager, Global Marketing
+ 1 215 568 0121
# # #